



September 12, 2023

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer, President, and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Chief Strategy Officer
Toshiya Kitagawa
(TEL. 03-6214-3600)

Notice Concerning Finalized Issuance of Stock Acquisition Rights (Paid Stock Options)

GNI Group (the Group) hereby announces that the details of the stock options (stock acquisition rights) issued by the Board of Directors on August 28, 2023 were finalized today as follows.

1	Name of Stock Acquisition Rights	51th Series of Stock Acquisition Rights
2	Number of Stock Acquisition Rights Offered	1,350
3	Type and number of shares to be issued upon exercise of Stock Acquisition Rights	Common stock 135,000 shares
4	Payment for Stock Acquisition Rights	The issue price per one Stock Acquisition Right shall be 22 yen
5	Amount of assets to be contributed upon exercise of Stock Acquisition Rights	209,500 yen per Stock Acquisition Right 2,095yen per share
6	Amount to be paid into capital when shares are issued upon exercise of Stock Acquisition Rights	1,047.5 yen per share
7	Number of persons receiving Stock Acquisition Rights	Company Executive: 1 Company Employees: 2 Total: 3

[Reference]

(1) Date of resolution by the Executive Officers August 28, 2023

(2) Allotment date September 12, 2023

About GNI Group, Inc.:

GNI Group is a global healthcare company listed on the Growth Board of the Tokyo Stock Exchange and engaged in drug discovery, pharmaceutical development, biomaterial development, clinical studies, manufacturing, and sales in both the United States and China. For more information, please visit our website below.

<https://www.gnipharma.com/>